Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YS9E
|
|||
| Former ID |
DNC007223
|
|||
| Drug Name |
4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol
|
|||
| Synonyms |
4-phenyl-5-(4-piperidyl)-3-isoxazolol
Click to Show/Hide
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H16N2O2
|
|||
| Canonical SMILES |
C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC=C3
|
|||
| InChI |
1S/C14H16N2O2/c17-14-12(10-4-2-1-3-5-10)13(18-16-14)11-6-8-15-9-7-11/h1-5,11,15H,6-9H2,(H,16,17)
|
|||
| InChIKey |
QTEBXBALJGPXEP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Inhibitor | [1] |
| GABA(A) receptor beta-2 (GABRB2) | Target Info | Inhibitor | [1] | |
| GABA(A) receptor gamma-2 (GABRG2) | Target Info | Inhibitor | [1] | |
| Gamma-aminobutyric acid receptor (GAR) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Serotonergic synapse | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| Iron uptake and transport | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. | |||
| REF 2 | 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships. J Med Chem. 2007 Apr 19;50(8):1988-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.